Last year, by Precision Oncology News’ count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. Although more and more biomarker-informed therapies are being developed and launched on the market, not all patients have access to them due to numerous barriers, among them difficulties accessing genetic testing, limited physician expertise, challenges setting up clinical trials in the community, and reimbursement pressures.
Patients’ social determinants of health also continue to influence whether they receive, or are even offered, biomarker testing and downstream treatment options.
In this panel, experts in the community treating diverse populations and tracking access challenges discuss the difficulties they are seeing and the solutions they’re working on to improve equity in precision oncology.
Kellie Jack of Weill Cornell Medicine, Raymond Osarogiagbon of Baptist Cancer Center, Rachit Kumar of Maine General Medical Center, and Greg Tranah of Sutter Health bring wide-ranging perspectives from small and large health systems across the U.S.